Bragadeesh R. Iyer, PharmD, BCGP, CSP

The study findings signal the need for improved equality in PrEP prescribing across various institutions and settings.

Investigators analyzed a series of disease-modifying therapies in a multi-decade trial.

Regardless, hygiene practices and prevention measures for SARS-CoV-2 should be strongly practiced to prevent all respiratory viruses.

BAT1706 was clinically equivalent to the reference bevacizumab for efficacy, safety, pharmacokinetics, and immunogenicity.

Patients readily accepted physical interventions and referrals to oncology clinical pharmacy practitioners.

Switching from adalimumab originator to SB5 did not cause clinically significant differences in treatment efficacy and safety for patients with noninfectious uveitis.

In the ambulatory setting, oncology pharmacists independently prescribe medications to support and manage therapy toxicities for cancer patients.

This study showed the importance of a multidisciplinary team’s expertise to investigate a clinical inquiry beyond the scope of the clinicians’ skillset and their access to necessary technology.